Discuss your analysis

Resources

Scientific resources and analytical context

Explore the published heritage of automated particle Raman analysis and discuss the technical information relevant to your application.

Regulatory and pharmacopoeial references

Regulatory and pharmacopoeial references

Regulatory and pharmacopoeial references

2026

Guideline on the pharmaceutical quality of inhalation and nasal medicinal products

EMA · EMEA/CHMP/QWP/49313/2005 Rev. 1 · Adopted guideline · Effective 1 February 2026

Sets quality expectations for inhalation and nasal medicinal products, including product-specific particle-size and performance considerations.

2018

Metered Dose Inhaler (MDI) and Dry Powder Inhaler (DPI) Drug Products — Quality Considerations

FDA · April 2018 draft · Nonbinding · Not for implementation

Section IV.F.7 proposes foreign-particulate tests and size-band acceptance criteria for MDI and DPI product specifications.

2022

European Commission EU GMP Annex 1: Manufacture of Sterile Medicinal Products

European Commission · Revised Annex 1 · In operation since 25 August 2023, with point 8.123 applicable since 25 August 2024

Sections 2 and 8 address contamination control in sterile manufacture, including inspection and investigation of defects in filled parenteral containers.

2003

FDA Bioavailability and Bioequivalence Studies for Nasal Aerosols and Nasal Sprays for Local Action

U.S. Food and Drug Administration · Draft guidance for industry · Revised: April 2003 · Not for implementation

The April 2003 draft discusses bioequivalence for locally acting nasal products and the role of drug particle-size characterization for nasal suspensions. Consult product-specific recommendations when planning a study.

USP–NF · Compendial chapter · Apply the edition and tests relevant to the product

Covers performance tests such as delivered-dose uniformity and particle-size testing, including aerodynamic sizing where applicable.

USP–NF · Compendial chapter · Revised text official 1 August 2026

Describes light-obscuration and microscopic counting for subvisible particulate matter in applicable parenteral preparations.

EDQM · Compendial chapter · Issue 13.1 revision takes effect 1 January 2027

Describes light-obscuration and microscopic counting for subvisible particles. Consult the applicable in-force Ph. Eur. text.

USP–NF · Compendial chapter

Sets out visual inspection and acceptance criteria for visible particulates in applicable injections.

USP–NF · Informational general chapter

Provides guidance on visual inspection of injections, including factors that affect detection and difficult-to-inspect products.

FDA · FDA-2021-D-0241 · December 2021 draft · Nonbinding · Not for implementation

Discusses visible particulate control for injectables, including particle identification, investigations and corrective actions. Subvisible particulates are outside its scope.

Technology Heritage & Patents

Technology Heritage & Patents

Technology Heritage & Patents

APSys / rap.ID developed an image-first workflow: automated microscopy located candidate particles before selective Raman measurement. Early patents combined detection, sizing and spectroscopic identification, anticipating the workflow later marketed as MDRS.

Automated particle-identification patent family

2001 substrate patent record

1999 APSys patent record

The first stainless-steel, touchscreen-controlled prototype was released in 2001. Development now spans more than 25 years and seven instrument generations.

Historical rap.ID experience refers to the predecessor companies and laboratories. SizeID.bio is the current particle-analysis offering of mibiC GmbH & Co. KG.